Literature DB >> 18702943

Co-associations between insulin sensitivity and measures of liver function, subclinical inflammation, and hematology.

Ian F Godsland1, Desmond G Johnston.   

Abstract

Clustering of risk factors for coronary heart disease and diabetes is well established, particularly in relation to insulin resistance. To determine whether evaluation of risk factor clustering will contribute to risk assessment, it is first necessary to discriminate co-association between risk factors from correlation. We undertook this in a large homogenous group, using a sophisticated measure of insulin sensitivity and a broad range of risk factors. Cross-sectional analysis of an occupational cohort using regression and factor analyses was performed. Subjects were 472 apparently healthy white men. The main outcome measures were insulin sensitivity, S(I), by minimal model analysis of the intravenous glucose tolerance test plus liver function and hematologic variables, including the inflammation indices, leukocyte count, and erythrocyte sedimentation rate. The S(I) correlated independently with serum gamma-glutamyl transferase (GGT), aspartate transaminase, and alkaline phosphatase activities; blood pressure; leukocyte count; and erythrocyte sedimentation rate (P < .01). On factor analysis, the factor that explained the greatest proportion of the variance (56.7%) included, in decreasing order of factor loading, triglycerides, S(I) (negative), body mass index, high-density lipoprotein cholesterol (negative), insulin, uric acid, and GGT activity (loadings >0.40). Mean arterial pressure was not a feature (loading 0.29), neither were indices of subclinical inflammation. In apparently healthy men, blood pressure and indices of subclinical inflammation do not cluster with other insulin resistance-related risk factors, despite correlating with insulin sensitivity. In contrast, both GGT activity and uric acid concentrations correlated with insulin sensitivity and co-associated with insulin resistance-related risk factors and are therefore components of a true risk factor cluster.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18702943     DOI: 10.1016/j.metabol.2008.04.010

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

1.  Chromium dinicocysteinate supplementation can lower blood glucose, CRP, MCP-1, ICAM-1, creatinine, apparently mediated by elevated blood vitamin C and adiponectin and inhibition of NFkappaB, Akt, and Glut-2 in livers of zucker diabetic fatty rats.

Authors:  Sushil K Jain; Jennifer L Croad; Thirunavukkarasu Velusamy; Justin L Rains; Rebeca Bull
Journal:  Mol Nutr Food Res       Date:  2010-09       Impact factor: 5.914

2.  Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey.

Authors:  Jeffrey C Sirota; Kim McFann; Giovanni Targher; Richard J Johnson; Michel Chonchol; Diana I Jalal
Journal:  Metabolism       Date:  2012-10-02       Impact factor: 8.694

3.  L-cysteine supplementation lowers blood glucose, glycated hemoglobin, CRP, MCP-1, and oxidative stress and inhibits NF-kappaB activation in the livers of Zucker diabetic rats.

Authors:  Sushil K Jain; Thirunavukkarasu Velusamy; Jennifer L Croad; Justin L Rains; Rebeca Bull
Journal:  Free Radic Biol Med       Date:  2009-03-26       Impact factor: 7.376

4.  A history of previous gestational diabetes mellitus is associated with adverse changes in insulin secretion and VLDL metabolism independently of increased intrahepatocellular lipid.

Authors:  S Forbes; I F Godsland; S D Taylor-Robinson; J D Bell; E L Thomas; N Patel; G Hamilton; K H Parker; I Marshall; C D Gray; D Bedford; M Caslake; B R Walker; D G Johnston
Journal:  Diabetologia       Date:  2013-06-13       Impact factor: 10.122

Review 5.  Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study.

Authors:  David M Maahs; Luiza Caramori; David Z I Cherney; Andrzej T Galecki; Chuanyun Gao; Diana Jalal; Bruce A Perkins; Rodica Pop-Busui; Peter Rossing; Michael Mauer; Alessandro Doria
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.